Premium
Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer
Author(s) -
Asare Elliot A.,
Evans Douglas B.,
Erickson Beth A.,
Aburajab Murad,
Tolat Parag,
Tsai Susan
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24316
Subject(s) - medicine , pancreatic cancer , neoadjuvant therapy , adjuvant therapy , adjuvant , value (mathematics) , cancer , health care , oncology , general surgery , intensive care medicine , breast cancer , machine learning , computer science , economics , economic growth
Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost‐effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost‐effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295 . © 2016 Wiley Periodicals, Inc.